In search of a targetable immune profile for acute myeloid leukemia.

Acute myeloid leukemia is a poor prognostic blood cancer with dismal survival rates. Major challenges in improving AML survivorship include its heterogeneity and ability to evade immunosurveillance. To facilitate subtyping and therapeutic decision-making, AML is risk stratified according to the genetic landscape, however, less is known about phenotypic differences and immune receptor signatures. Immune profiling of cancer cells is complex and a key determinant of tumor progression. In addition to influencing disease management, an understanding of cell surface immune receptor profiles provides key information on how different AML subgroups evade surveillance. Several robust studies aimed at characterizing the immune profile of cancer cells and gaining a deeper understanding of their function as cellular markers, have provided key information within the field. This review aims to compile information on the immune profiles of AML, understand their role in immune evasion, therapy responses, recurrence, and outcomes.